11-酮氟前列腺素 | 62145-07-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 11-酮氟前列腺素
• 英文名称: 11-keto fluprostenol
• 英文别名: (Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]-3-oxocyclopentyl]hept-5-enoic acid
• CAS: 62145-07-7
• 化学式: C₂₃H₂₇F₃O₆
• 分子量: 456.459
• InChiKey: MDMHJAKZGBRYTF-KYUUVOLFSA-N

物化性质

• 沸点：
  627.3±55.0 °C(Predicted)
• 密度：
  1.331±0.06 g/cm3(Predicted)
• 溶解度：
  PBS (7.2): 29 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  32
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• PROSTAGLANDIN ANALOGS AND USES THEREOF
  申请人：Lifex Biolabs, Inc.

  公开号：US20210139435A1

  公开（公告）日：2021-05-13

  The present invention relates to pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, including, as an active ingredient, a prostaglandin analog or a pharmaceutically acceptable salt thereof, wherein the compound has excellent effects in inducing Nurr1, and thus, can be useful as a pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, in particular, cancer, autoimmune disease such as rheumatoid arthritis, schizophrenia, manic depression and neurodegenerative disease such as Alzheimers disease or Parkinson's disease.

  本发明涉及一种药物组合物，用于预防或治疗与Nurr1相关的疾病、紊乱或状况，其中包括作为活性成分的前列腺素类似物或其药学上可接受的盐，该化合物具有良好的诱导Nurr1的效果，因此，可用作预防或治疗与Nurr1相关的疾病、紊乱或状况的药物组合物，特别是癌症、自身免疫性疾病如类风湿关节炎、精神分裂症、躁郁症以及神经退行性疾病如阿尔茨海默病或帕金森病。
• COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS
  申请人：Lipkin Pamela

  公开号：US20100074857A1

  公开（公告）日：2010-03-25

  The described invention relates to the formulation and delivery of compositions to treat an epithelial-related condition selected from the group consisting of sparse hair growth, short hair growth, thin hair growth, alopecia and hair depigmentation and methods for their use. In some embodiments, the composition contains a first component and a second component wherein the first component is at least one prostaglandin analog and the second component is at least one imidazole analog, such that the at least one imidazole analog improves the efficacy of the at least one prostaglandin analog when delivered to a subject refractory to the effect of the prostaglandin analog alone.
• US4346228A
  申请人：——

  公开号：US4346228A

  公开（公告）日：1982-08-24